Journal of the American Academy of Dermatology · 2026
Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Iversen Lars, Langley Richard G, Gudjonsson Johann E, Eidsmo Liv, Narbutt Joanna, Czajkowski Rafal, Pinter Andreas, Pink Andrew E, Rivera-Diaz Raquel, Gianchandani Dheeraj A, Kolbinger Frank, Bao Weibin, Gaillez Corine, Jagiello Piotr, Conrad Curdin
Аннотация
BACKGROUND: Benefits of early intervention with secukinumab in patients with new-onset plaque psoriasis (disease duration: ≤1 year) were investigated in STEPIn study (NCT03020199).
OBJECTIVE: To evaluate the proportion of patients maintaining sustained skin clearance in the treatment-free follow-up period up to week (W) 104 following withdrawal of secukinumab and narrow band ultraviolet B at W52.
METHODS: Wald test was used for analysis of proportion of patients achieving PASI 90 (key secondary endpoint) from W52 through W104. Missing values were imputed using nonresponder imputation approach.
RESULTS: Overall, 93.5% (72/77) of patients completed 52 weeks in the secukinumab arm. At W104, 20.8% of patients who previously received secukinumab sustained PASI 90 responses. At W104, 11.7%, 22.1%, and 24.7% of patients previously treated with secukinumab sustained a PASI 100 response, IGA mod 2011 0/1 and PASI <3. Among secukinumab treated patients, 44% (29/66) who entered the treatment-free follow-up period at W52 did not relapse (loss of 50% of the maximum improvement in PASI following treatment cessation) until W104.
LIMITATION: Absence of blinding due to open-label nature of the study.
CONCLUSIONS: Early intervention with secukinumab maintains efficacy in a subset of patients with new-onset moderate to severe psoriasis, 1-year following treatment withdrawal.
OBJECTIVE: To evaluate the proportion of patients maintaining sustained skin clearance in the treatment-free follow-up period up to week (W) 104 following withdrawal of secukinumab and narrow band ultraviolet B at W52.
METHODS: Wald test was used for analysis of proportion of patients achieving PASI 90 (key secondary endpoint) from W52 through W104. Missing values were imputed using nonresponder imputation approach.
RESULTS: Overall, 93.5% (72/77) of patients completed 52 weeks in the secukinumab arm. At W104, 20.8% of patients who previously received secukinumab sustained PASI 90 responses. At W104, 11.7%, 22.1%, and 24.7% of patients previously treated with secukinumab sustained a PASI 100 response, IGA mod 2011 0/1 and PASI <3. Among secukinumab treated patients, 44% (29/66) who entered the treatment-free follow-up period at W52 did not relapse (loss of 50% of the maximum improvement in PASI following treatment cessation) until W104.
LIMITATION: Absence of blinding due to open-label nature of the study.
CONCLUSIONS: Early intervention with secukinumab maintains efficacy in a subset of patients with new-onset moderate to severe psoriasis, 1-year following treatment withdrawal.